Millington Financial Advisors LLC Purchases 1,773 Shares of Sanofi (NASDAQ:SNY)

Millington Financial Advisors LLC increased its position in shares of Sanofi (NASDAQ:SNY) by 9.8% in the fourth quarter, Holdings Channel.com reports. The firm owned 19,864 shares of the company’s stock after purchasing an additional 1,773 shares during the quarter. Millington Financial Advisors LLC’s holdings in Sanofi were worth $988,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in SNY. NewSquare Capital LLC increased its stake in Sanofi by 3.6% in the fourth quarter. NewSquare Capital LLC now owns 106,697 shares of the company’s stock worth $5,239,000 after purchasing an additional 3,723 shares during the period. GAMMA Investing LLC purchased a new position in Sanofi in the 4th quarter worth about $81,000. Parkside Financial Bank & Trust lifted its holdings in Sanofi by 435.2% during the 4th quarter. Parkside Financial Bank & Trust now owns 2,189 shares of the company’s stock valued at $109,000 after buying an additional 1,780 shares in the last quarter. Jennison Associates LLC purchased a new stake in Sanofi in the 4th quarter valued at about $7,932,000. Finally, OLD National Bancorp IN grew its stake in Sanofi by 5.9% in the 4th quarter. OLD National Bancorp IN now owns 28,379 shares of the company’s stock worth $1,411,000 after acquiring an additional 1,572 shares in the last quarter. 10.04% of the stock is currently owned by institutional investors.

Sanofi Stock Up 1.1 %

Shares of SNY traded up $0.54 during mid-day trading on Tuesday, hitting $47.69. The company’s stock had a trading volume of 1,664,859 shares, compared to its average volume of 1,914,748. The company has a current ratio of 1.27, a quick ratio of 0.87 and a debt-to-equity ratio of 0.19. The company’s 50-day moving average is $47.58 and its 200-day moving average is $48.45. Sanofi has a 52-week low of $42.63 and a 52-week high of $57.82. The firm has a market capitalization of $120.64 billion, a price-to-earnings ratio of 20.21, a PEG ratio of 1.62 and a beta of 0.61.

Sanofi (NASDAQ:SNY) last posted its earnings results on Thursday, February 1st. The company reported $0.89 earnings per share for the quarter, missing analysts’ consensus estimates of $0.94 by ($0.05). Sanofi had a return on equity of 27.47% and a net margin of 12.56%. The company had revenue of $11.76 billion for the quarter, compared to analysts’ expectations of $13.02 billion. On average, equities research analysts forecast that Sanofi will post 4.11 EPS for the current fiscal year.

Sanofi Increases Dividend

The business also recently announced an annual dividend, which will be paid on Thursday, June 6th. Shareholders of record on Friday, May 10th will be paid a $1.478 dividend. This represents a yield of 2.98%. The ex-dividend date is Thursday, May 9th. This is a positive change from Sanofi’s previous annual dividend of $1.38. Sanofi’s payout ratio is 58.47%.

Analyst Ratings Changes

SNY has been the subject of several research analyst reports. Morgan Stanley initiated coverage on shares of Sanofi in a research note on Tuesday, January 23rd. They set an “equal weight” rating and a $55.00 price target for the company. StockNews.com lowered Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, February 27th. Finally, TheStreet cut Sanofi from a “b” rating to a “c” rating in a report on Friday, February 9th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, Sanofi currently has an average rating of “Hold” and an average price target of $55.00.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.